Biomark Diagnostics Inc. develops early-stage cancer diagnostic technology platform to detect and treat cancer. The company invests in and develops a liquid biopsy metabolic panel assay for the early-stage diagnosis of lung cancer and glioblastoma (GBM) breast cancer. It is also developing liquid biopsy tests for various cancer types, including glioblastoma, gastrointestinal, prostate, head, neck cancers. The company was incorporated in 2014 and is headquartered in Richmond, Canada.…
BioMark Announces Participation in upcoming MSACL 2026 and BIOHorizon 2026 Life Sciences Conferences
Biomark Diagnostics (CNSX: BUX) is listed on the Canadian Securities Exchange, where its shares trade in CAD. It belongs to the Diagnostics & Research industry, part of the Healthcare sector.
The shares were at 0.4000 CAD on 20 November 2026, up 11.1% over 52 weeks. Its 52-week range is 0.2700 CAD to 0.6400 CAD: the price is 37.5% below the high and 48.1% above the low.
Its market capitalisation is 42.59M CAD.
Biomark Diagnostics reports return on equity of -446.2% and revenue down 82.0% year over year.
Its debt exceeds its cash by 482.90K CAD, a debt-to-equity ratio of 2.19. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.
No upcoming events tracked.